Sotalol

Sotalol, sold as Betapace and Betapace AF, is a medicine taken by mouth that the US label describes as an antiarrhythmic, a medicine for heart rhythm problems, with both beta-blocking properties and properties that lengthen the heart's action potential. The label read, one label for the two brands, lists two uses: the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (the label says it has not been shown to enhance survival in these patients); and keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are currently in sinus rhythm. It carries a boxed warning about life-threatening proarrhythmia, a drug-caused worsening of heart rhythm.

Also called Betapace · Betapace AF

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 9947 (sotalol); the label names the salt sotalol hydrochloride (RxNorm 7008, UNII HEC37C70XX, a broad match to the ingredient). MeSH descriptor D013015 is Sotalol. RxClass lists the FDA established pharmacologic class Antiarrhythmic (the page files under that class), a beta-receptor antagonist mechanism class and the physiologic effect Cardiac Rhythm Alteration. The label read is the Legacy Pharma USA, Inc. label for Betapace and Betapace AF, application NDA019865 in openFDA, effective 2024-12-16; Drugs@FDA lists Betapace AF under its own application NDA021151. Sotylize oral solution (NDA205108), Sorine and generic sotalol labels, and sotalol injection labels, were not read. This page records label indications, the class, the mechanism sentence and the title and first sentence of the boxed warning only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties.

Classification codes

  • UNII HEC37C70XX Sotalol hydrochloride

Claims and evidence

Context Patients taking sotalol, as described in a US Betapace and Betapace AF label boxed warning

Recipient
Recipient not specified
Population
Patients who take the medicine, as the boxed warning describes the risk. The passages read give no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients taking Betapace or Betapace AF
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label carries a boxed warning titled life-threatening proarrhythmia. It says the medicine can cause life-threatening ventricular tachycardia associated with QT interval prolongation.

    Applies to Recipient not specified Patients taking sotalol, as described in a US Betapace and Betapace AF label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the title and first statement of the label's boxed warning only. The warning goes on to tell prescribers where treatment is started and what to do if the QT interval lengthens; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], title
      How it applies
      Label passage quoted in the research quote table (LB-10).
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].boxed_warning[0], first paragraph
      How it applies
      Label passage quoted in the research quote table (LB-11).
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241216.
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF

Recipient
Recipient not specified
Population
Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia
  • Patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.

    Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Supports openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], indications statement
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.1 Life-Threatening Ventricular Arrhythmias
      How it applies
      Label passage quoted in the research quote table (LB-05, LB-06).
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter (AFIB/AFL)
      How it applies
      Label passage quoted in the research quote table (LB-07, LB-08).
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Background openFDA drug label record for Betapace and Betapace AF (sotalol hydrochloride tablets), Legacy Pharma USA, Inc. label: indications, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id a6a7702f-36c9-45db-b640-453dc324baee (manufacturer Legacy Pharma USA, Inc., application NDA019865; one label for the two brands Betapace and Betapace AF), returned on 2026-11-18. The label text is dated 2024-12-16 (effective_time). Other openFDA records of sotalol labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20241216.
      Retrieved
      Source effective date
      2024-12-16
      Source state
      Current
      Version fingerprint
      c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:sotalol
Content hash
61ddc3b488b89f12cb4c6a6bbdaf8a89a1be478df909dddf25fc477fbe61566f